Sangha Enterprises Inc

Bayside Biosciences Inc is located in Santa Clara, California, and specializes in providing innovative solutions in the biosciences sector. The company is dedicated to advancing research and development through strategic partnerships and a commitment to excellence in its services. With a focus on collaboration and cutting-edge technology, Bayside Biosciences Inc aims to support the scientific community in achieving significant breakthroughs. Their expertise and resources position them as a valuable player in the biosciences industry. Generated from the website

AceLink Therapeutics, Inc. is a clinical-stage drug development company based in Newark, CA, specializing in groundbreaking therapies for diseases related to glycolipid metabolism. The company boasts a seasoned team of professionals with extensive knowledge in glycolipid biology, rare genetic diseases, and drug development, collaborating with a broad network of research organizations and academic leaders. Among its lead programs, AL1211 is a non-brain penetrant glucosylceramide synthase (GCS) inhibitor currently undergoing Phase 2 trials for Fabry disease and type I Gaucher disease. Additionally, AL0804, a highly brain-penetrant GCS inhibitor, targets neuronopathic glycolipid storage diseases, while AL1311 is a potent NRF2 activator being developed for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Generated from the website

Quadriga Biosciences, Inc., located in Los Altos, CA, is focused on advancing innovative oncology therapeutics, particularly through its novel chemotherapeutic agent, QBS72S. This first-in-class drug leverages the L-type Amino Acid Transporter 1 (LAT1) to penetrate the blood-brain barrier and target rapidly growing cancer cells. By mimicking the structure of an aromatic amino acid, QBS72S acts as a Trojan Horse, facilitating its entry into cancer cells where it induces cell death through the formation of DNA interstrand cross-links. The company is comprised of leaders in oncology drug development, dedicated to overcoming barriers to cancer treatment. Generated from the website